Chronic Kidney Disease Clinical Evidence and Research: What the Studies Show

Introduction

The four-pillar approach to CKD didn’t appear out of nowhere. It came from a series of large randomized trials over the last 6-7 years that genuinely changed practice. This article walks through the most important ones in chronological order, what they showed, and how they fit together to inform KDIGO 2024.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey, and you can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

RENAAL and IDNT: The Original ARB Renal Trials

Setting the stage. RENAAL (Brenner et al., NEJM, 2001) randomized 1,513 patients with T2D and nephropathy to losartan 50-100 mg or placebo. Over 3.4 years, losartan reduced the composite of doubling of serum creatinine, ESRD, or death by 16% (HR 0.84, p=0.02). This was the first big proof that an ARB protected diabetic kidneys beyond BP effect.

Quick Answer: CREDENCE (NEJM, 2019) established canagliflozin’s renal benefit in T2D with CKD: 30% reduction in renal events

IDNT (Lewis et al., NEJM, 2001) ran in parallel with irbesartan in T2D nephropathy. 1,715 patients, similar design. Irbesartan reduced the same composite by 20%. Both trials together established ACE/ARB as foundation therapy for diabetic CKD with proteinuria.

These trials anchor the current ACE/ARB pillar. Despite being over two decades old, they remain the strongest direct evidence for this drug class in CKD.

EMPA-REG OUTCOME: The SGLT2 Surprise

Empagliflozin was approved as a glucose drug in 2014. EMPA-REG OUTCOME (Zinman et al., NEJM, 2015) was a CV safety trial required by FDA. 7,020 T2D patients with CV disease randomized to empagliflozin 10 or 25 mg vs placebo.

The CV death reduction (38%, HR 0.62) startled the field. The kidney findings were almost an afterthought at the time but extraordinary in retrospect: 39% reduction in incident or worsening nephropathy (HR 0.61, p<0.001), 44% reduction in doubling of creatinine, and 55% reduction in initiation of renal replacement therapy.

This trial planted the seed. SGLT2 inhibitors weren’t just glucose drugs; they were doing something fundamental for kidneys.

CREDENCE: The Dedicated SGLT2 Renal Trial

CREDENCE (Perkovic et al., NEJM, 2019) was the first dedicated SGLT2i renal outcomes trial. 4,401 patients with T2D and CKD (eGFR 30-90, UACR 300-5000) randomized to canagliflozin 100 mg or placebo. Stopped early at planned interim analysis after a 30% reduction in primary composite (ESKD, doubling of creatinine, renal or CV death; HR 0.70, p=0.00001).

CREDENCE separately showed 32% reduction in CV death, MI, or stroke and 39% reduction in heart failure hospitalization. The trial established SGLT2i as kidney-protective beyond glucose effect and beyond CV protection.

Number needed to treat (NNT): about 22 patients for 2.5 years to prevent one major kidney or CV event. That’s an unusually strong NNT for chronic disease therapy.

DAPA-CKD: Extending to Non-diabetic CKD

DAPA-CKD (Heerspink et al., NEJM, 2020) was the trial that broke the diabetes-only paradigm. 4,304 patients with CKD (eGFR 25-75, UACR 200-5000), only 67% with T2D. Dapagliflozin 10 mg vs placebo. Stopped early.

Primary composite (sustained eGFR decline ≥50%, ESKD, renal or CV death) reduced 39% (HR 0.61, p<0.001). Benefit was consistent in diabetic and non-diabetic subgroups, which was the major surprise. All-cause mortality reduced 31% (HR 0.69, p=0.004).

This trial expanded the SGLT2 indication far beyond diabetes. Glomerular diseases like IgA nephropathy and FSGS now had evidence-based pharmacotherapy beyond ACE/ARB for the first time.

FIDELIO-DKD: Finerenone Enters

FIDELIO-DKD (Bakris et al., NEJM, 2020) studied finerenone, a nonsteroidal MRA, in 5,734 patients with T2D and CKD (eGFR 25-75, UACR 30-5000) on max-tolerated ACE/ARB. Finerenone 10-20 mg vs placebo over 2.6 years.

Primary kidney composite (kidney failure, sustained eGFR decline ≥40%, renal death) reduced 18% (HR 0.82, p=0.001). Secondary CV composite reduced 14%. Hyperkalemia leading to discontinuation occurred in 2.3% of finerenone vs 0.9% placebo, manageable but real.

This trial established finerenone as a viable add-on to background ACE/ARB in diabetic CKD with albuminuria.

FIGARO-DKD: Cardiovascular Benefit Confirmed

FIGARO-DKD (Pitt et al., NEJM, 2021) studied finerenone in a less advanced CKD population than FIDELIO. 7,437 patients with T2D and CKD (mostly G2-G3 with albuminuria). Primary endpoint was CV composite this time.

CV composite (CV death, nonfatal MI, nonfatal stroke, HF hospitalization) reduced 13% (HR 0.87, p=0.03). Kidney composite as secondary endpoint reduced 13% (numerically lower but consistent). HF hospitalization specifically dropped 29%.

Together with FIDELIO, this established finerenone benefit across the CKD spectrum from early albuminuric disease to advanced CKD.

FIDELITY: The Pooled Analysis

FIDELITY (Agarwal et al., Eur Heart J, 2022) pooled the individual patient data from FIDELIO and FIGARO. 13,026 patients combined. The larger sample allowed subgroup analyses and more precise effect estimates.

Cardiovascular composite reduced 14%. Kidney composite reduced 23%. Benefits consistent across baseline eGFR, albuminuria, age, and sex. Hyperkalemia leading to discontinuation 1.7% finerenone vs 0.6% placebo.

FIDELITY is the standard reference for finerenone effects in diabetic CKD.

EMPA-KIDNEY: Broadest SGLT2i Evidence

EMPA-KIDNEY (Herrington et al., NEJM, 2023) extended SGLT2i evidence to a broader CKD population. 6,609 patients with eGFR 20-45 regardless of albuminuria, or eGFR 45-90 with UACR ≥200. Empagliflozin 10 mg vs placebo. Stopped early at median 2.0 years.

Primary composite (kidney disease progression or CV death) reduced 28% (HR 0.72, p<0.001). Hospitalization for any cause reduced 14%.

EMPA-KIDNEY enrolled a much broader population than CREDENCE or DAPA-CKD, including patients with no albuminuria and patients with non-diabetic CKD. The benefit held across this broader group.

SUSTAIN 6 and LEADER: GLP-1 Kidney Signals

SUSTAIN 6 (Marso et al., NEJM, 2016) tested semaglutide 0.5 or 1 mg weekly in 3,297 T2D patients with high CV risk. Primary endpoint was MACE; renal outcomes were prespecified secondary.

New or worsening nephropathy (defined as new macroalbuminuria, doubling of creatinine, ESKD, or renal death) reduced 36% with semaglutide (HR 0.64, p=0.005). The signal was driven primarily by reduction in new macroalbuminuria.

LEADER (Marso et al., NEJM, 2016) with liraglutide 1.8 mg in 9,340 T2D patients showed similar findings. Composite renal outcome reduced 22% (HR 0.78, p=0.003). REWIND with dulaglutide and AWARD with other GLP-1 RAs showed consistent secondary signals.

These trials suggested GLP-1 RA had kidney benefit but didn’t establish it as a primary endpoint until FLOW.

FLOW: GLP-1 Enters the Kidney Pillar

FLOW (Perkovic et al., NEJM, 2024) was designed as a dedicated kidney outcomes trial. 3,533 patients with T2D and CKD (eGFR 25-75, UACR 100-5000). Semaglutide 1 mg weekly subcutaneous vs placebo on top of standard care including ACE/ARB.

Primary composite (kidney failure, sustained ≥50% eGFR decline, kidney death, or CV death) reduced 24% (HR 0.76, 95% CI 0.66-0.88, p=0.0003). Trial stopped early at second interim analysis.

Component breakdown: kidney-specific composite reduced 21%, CV death reduced 29%, all-cause mortality reduced 20% (HR 0.80). Number needed to treat: 20 patients for the duration of the trial to prevent one major event.

Subgroup consistency was strong. Benefit appeared regardless of baseline eGFR, baseline UACR, SGLT2i use, or background ACE/ARB. Adverse events: GI side effects more common (nausea 27% vs 18%), but serious adverse events similar between groups.

FLOW closed the loop. GLP-1 RA is now established as kidney-protective in T2D + CKD and got incorporated into KDIGO 2024 as the fourth pillar.

SURPASS-4: Tirzepatide Secondary Kidney Findings

SURPASS-4 (Del Prato et al., Lancet, 2021) compared tirzepatide to insulin glargine in 2,002 T2D patients with elevated CV risk over 52 weeks. Primary endpoint was glucose; kidney was secondary.

A post-hoc analysis (Heerspink et al., Lancet Diabetes Endocrinol, 2022) found 41% slower eGFR decline with tirzepatide vs glargine in patients with CKD at baseline. UACR reduced 30-40% across tirzepatide doses.

This is suggestive but not definitive. A dedicated tirzepatide kidney outcomes trial is in design.

STEP and SELECT: GLP-1 in Non-diabetic Populations

SELECT (Lincoff et al., NEJM, 2023) tested semaglutide 2.4 mg weekly in 17,604 patients with overweight/obesity and established CV disease but no diabetes. Primary endpoint was MACE, reduced 20%.

Kidney composite as secondary endpoint reduced 22%. While this isn’t dedicated CKD evidence, it suggests GLP-1 kidney benefit may extend to non-diabetic populations. Dedicated nondiabetic CKD trials are still needed.

The STEP weight management trials separately showed UACR reductions in obese patients with elevated baseline values, consistent with kidney protective signal in non-diabetic obese populations.

KDIGO 2024 Guideline Synthesis

KDIGO published its updated Diabetes in CKD guideline in 2024 incorporating the FLOW data. Key recommendations:

1. ACE/ARB at maximum tolerated dose for proteinuric CKD (Grade 1A)
2. SGLT2 inhibitor for T2D + CKD with eGFR ≥20 (Grade 1A)
3. SGLT2 inhibitor for non-diabetic CKD with eGFR ≥20 and proteinuria (Grade 1A)
4. Finerenone for T2D + CKD with persistent albuminuria on max-tolerated ACE/ARB (Grade 1A)
5. GLP-1 RA for T2D + CKD with eGFR ≥15 not at glycemic target on metformin and SGLT2i (Grade 1B for cardiorenal protection)
6. BP target <120/80 if tolerated (Grade 1A)
7. Multidisciplinary team involvement for advanced CKD

The strength of these recommendations reflects high-quality randomized evidence. Few areas of medicine have this level of evidence-based standard care.

Key Takeaway: FIDELIO-DKD (NEJM, 2020) and FIGARO-DKD (NEJM, 2021) built finerenone evidence in diabetic CKD

Trials That Didn’t Pan Out

Bardoxolone in BEACON (NEJM, 2013) showed signal early but increased CV events and was stopped. ROADMAP with olmesartan didn’t show kidney benefit. SAVOR-TIMI 53 with saxagliptin showed neutral renal effects. These reinforce that not every plausible mechanism translates to outcomes.

What’s Coming Next

Several trials in progress could shift practice further by 2027.

ZENITH-CKD (atrasentan in IgA nephropathy): endothelin antagonist with proteinuria reduction.

EMPACT-MI extensions: empagliflozin in post-MI populations including CKD subgroups.

PROTEIN-CKD: dietary protein intervention in CKD progression.

STEP-CKD and similar: dedicated GLP-1 kidney trials in non-diabetic populations.

Tirzepatide kidney outcome trial (announced but not yet enrolling).

The field is unusually active right now. The four-pillar standard may be five pillars within a few years.

Limitations of Current Evidence

A few honest caveats. Most trials enroll the patients most likely to benefit (proteinuric, recently diagnosed, well-controlled BP). Real-world effects may be smaller. Trial follow-up is generally 2-4 years; long-term effects beyond 5 years are mostly extrapolated.

Specific populations are underrepresented. Older adults over 75, patients with frailty, those with limited life expectancy, and patients on dialysis are less studied. Pediatric CKD has its own evidence base, generally smaller.

Cost-effectiveness varies substantially across these drugs. SGLT2 inhibitors and GLP-1 RAs are expensive, and access depends on insurance coverage and patient assistance programs. The cost barrier is real even when the clinical evidence is strong.

Implications for Clinical Practice

The trials together support a sequenced approach: ACE/ARB if proteinuric or hypertensive, SGLT2i for any CKD with eGFR ≥20, finerenone for diabetic CKD with persistent albuminuria, GLP-1 RA for T2D + CKD especially when glycemic and weight targets aren’t met. Lifestyle and BP control underlie everything.

Patients who get all four pillars when eligible see substantial cumulative benefit. Patients who get fewer still benefit, but proportionately less. The data argues for aggressive implementation.

Trial-by-trial Methodology Notes

Sample Sizes and Follow-up

The major SGLT2 and GLP-1 trials enrolled between 3,500 and 17,000 patients with median follow-up of 2-4 years. This sample size and duration is necessary to detect outcome differences in a chronic disease with relatively low annual event rates. Smaller trials tend to be underpowered for hard outcomes.

Composite Endpoints

Most CKD trials use composite endpoints (combining several types of bad outcomes) to gain statistical power. The trade-off is that the composite may be driven by one component while others show neutral effects. Reading the components individually matters.

For example, FIDELIO-DKD’s primary kidney composite was driven primarily by albuminuria progression and eGFR slope, with smaller contribution from hard kidney failure events. FLOW’s composite was more balanced across kidney failure, eGFR decline, and CV death.

Surrogate vs Hard Endpoints

Albuminuria reduction is a surrogate. eGFR slope is a surrogate. ESKD initiation is a hard endpoint. Death is the hardest endpoint. Trials that show benefit on hard endpoints are more compelling than those showing only surrogate improvements.

The PRIORITY consortium analyses (CJASN, 2019) demonstrated that albuminuria reduction predicts subsequent ESKD reduction, validating it as a surrogate. eGFR slope similarly validated. Both surrogates plus the hard endpoints in the major trials produce a coherent picture.

Patient Populations

DAPA-CKD enrolled UACR 200-5000 with eGFR 25-75. EMPA-KIDNEY enrolled UACR ≥200 OR eGFR 20-45 regardless of albuminuria. CREDENCE required UACR 300-5000 and eGFR 30-90 with T2D. These differences matter when extrapolating to your specific patient.

FLOW required UACR ≥100 with eGFR 50-75, OR UACR ≥300 with eGFR 25-50. The albuminuria threshold is lower than CREDENCE but the trial enrolled more advanced CKD overall.

Putting Evidence Into Practice

Reading trial results is one thing. Implementing them is another. A few practical observations:

Adoption lags evidence by 3-7 years on average. SGLT2 inhibitors took 5+ years from EMPA-REG OUTCOME to become standard CKD care. GLP-1 RA in CKD will likely take similar time despite the FLOW data being unambiguous.

Specialty matters. Nephrologists adopt new evidence faster than primary care for kidney-specific drugs. Endocrinologists adopt faster than nephrologists for GLP-1 RA. Cross-specialty coordination becomes a key implementation challenge.

Cost shapes use. SGLT2 inhibitors cost -600/month. GLP-1 RAs cost -1300/month. Even with insurance, copays can reach -200/month, which limits adherence.

Patient education matters. A patient who understands why they’re on four medications adheres better than one who just gets pills handed over. Discussion of mechanism (without overselling) helps.

Reading Trial Publications Yourself

Most major CKD trials are published in NEJM with full text accessible via abstracts and often via NEJM’s free preview. The FDA briefing documents for drug approvals often summarize key trials in clinically useful ways. The KDIGO guidelines themselves are freely available at kdigo.org and walk through evidence systematically.

For patients who want to dig in, a few good resources: the NIH ClinicalTrials.gov database for ongoing trials, the National Kidney Foundation patient-facing summaries of major trials, and the USRDS annual data report for population-level trends.

How TrimRx Uses This Evidence

We translate KDIGO 2024 into our prescribing protocols. For T2D + CKD patients with eGFR ≥15, we consider GLP-1 RA appropriate based on FLOW and KDIGO. We coordinate with the patient’s nephrologist and primary care. We don’t prescribe in dialysis patients. We require recent labs before initiation in patients with eGFR under 45.

The evidence base is strong enough that GLP-1 RA in T2D + CKD is no longer experimental or off-guideline. It’s the standard of care.

A Historical Perspective

Twenty-five years ago, the entire CKD pharmacopeia for nephroprotection was ACE inhibitors plus blood pressure control plus glucose control. Patients with diabetic nephropathy progressed to dialysis at predictable rates, and dialysis was the destination most patients reached.

Today’s quadruple therapy was unimaginable in 2000. Each new pillar reduced risk by 15-40% relative, and stacked together they have substantially flattened the historical decline curves. Patients who would have started dialysis in their 60s in 2000 now often hold function into their 80s.

This is one of the genuine therapeutic success stories in chronic disease over the last quarter century. The challenge now is implementation: getting eligible patients on the drugs that will help them, especially across socioeconomic lines where access has been uneven.

What Evidence Is Missing

Despite the strong trial portfolio, gaps remain. We lack head-to-head trials comparing different drugs within and across classes. We lack data in patients on dialysis. We lack data in Black, Hispanic, and Asian populations proportionate to their CKD burden in the US (most trials skew white European). We lack long-term safety data beyond 4-5 years on the newer drugs. We lack evidence in pediatric CKD beyond ACE/ARB.

Trials underway address some of these gaps. Many won’t read out for years.

A Note on Conflicts of Interest

Most large CKD trials are industry-sponsored. The trials are well-designed and rigorously analyzed, but interpretation always benefits from independent perspective. KDIGO’s guideline development process explicitly addresses conflicts and incorporates non-industry investigators.

Independent registries (like the USRDS, the UK Renal Registry, and various European national kidney registries) provide real-world data that complements industry trials. Effect sizes in real-world data are often somewhat smaller than in trials, reflecting differences in adherence, monitoring, and patient selection.

Closing Thought

The evidence base for modern CKD care is one of the best in any chronic disease. Few areas of medicine have four medication classes with high-quality randomized evidence for hard endpoints. The challenge isn’t whether the drugs work; that’s clear. The challenge is access, implementation, and adherence over the years and decades that CKD care requires.

Myth vs. Fact: Setting the Record Straight

Misconceptions about treatment can delay good decisions. Here are three worth correcting before you make any choices about your care.

Myth: If your creatinine is normal, your kidneys are fine. Fact: Creatinine is a late marker. Albuminuria (protein in urine) appears years earlier and is part of the standard CKD staging system. Both eGFR and UACR should be tracked together.

Myth: Once you have CKD, decline is inevitable. Fact: The FLOW trial (2024) showed semaglutide reduced kidney failure and CV death by 24 percent in T2D patients with CKD. SGLT2 inhibitors (DAPA-CKD, EMPA-KIDNEY) provide similar protection. Modern CKD care can substantially slow or halt progression.

Myth: Drinking more water helps your kidneys. Fact: In patients without dehydration, more water doesn’t help kidney function. In advanced CKD it can cause fluid overload. Hydration goals should be set with your nephrologist, not based on the 8-glasses myth.

The Path Forward with TrimRx

Managing your metabolic health shouldn’t be a journey you take alone. The science behind GLP-1 medications offers a new level of hope for people facing chronic kidney disease and the related challenges that come with it. By addressing root hormonal and metabolic causes, these treatments provide a path toward more stable energy, better cardiovascular health, and improved quality of life.

At TrimRx, we’re committed to providing an empathetic and transparent experience. We understand the frustrations of traditional healthcare: the long waits, the unclear costs, and the lack of personalized care. Our platform is designed to put you back in control of your health. By combining clinical expertise with modern technology, we help you access the treatments you need while providing the 24/7 support you deserve.

Our program includes:

• Doctor consultations: professional guidance without the in-person waiting room
• Lab work coordination: baseline health markers monitored properly
• Ongoing support: 24/7 access to specialists for dosage changes and side effect management
• Reliable medication access: FDA-registered, inspected compounding pharmacies prepare Compounded Semaglutide or Compounded Tirzepatide when branded medications aren’t the right fit

Sustainable health is about more than a number on a scale or a single lab result. It’s about feeling empowered in your own body. Whether you’re starting to research your options or ready to take the next step with a free assessment, we’re here to guide you with science-backed, personalized care.

Bottom line: TrimRx provides a streamlined, medically supervised path to access the latest advancements in chronic kidney disease and weight management, all from the comfort of home.

FAQ

How Big Are the Absolute Risk Reductions?

Modest. Typical 3-year absolute risk reduction for major events in these trials is 2-5 percentage points. NNT in the 20-30 range. Cumulative over years, this adds up substantially, but no single trial shows a dramatic short-term shift.

Why Was FLOW Stopped EARLY?

A prespecified interim analysis showed clear efficacy crossing the predetermined boundary. Continuing the trial would have denied benefit to placebo patients, considered ethically problematic.

Is the Evidence for Non-diabetic CKD as Strong?

For SGLT2 inhibitors, yes (DAPA-CKD enrolled 33% non-diabetic patients with consistent benefit). For GLP-1 RA, no, dedicated non-diabetic CKD trials haven’t read out. ACE/ARB evidence is mostly in diabetic populations though mechanism applies broadly.

What About Pediatric CKD?

Smaller evidence base. Most pediatric CKD has different etiology (congenital anomalies, glomerulonephritis). ACE/ARB use is established. SGLT2i and GLP-1 RA are not currently standard in pediatric CKD outside specific indications.

How Often Do Guidelines Change?

KDIGO updates its CKD guidelines roughly every 3-4 years. The 2024 update incorporated FLOW. The next update will likely include tirzepatide and any new trial data through 2027.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.